Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more
DYN is expected to report earnings to rise 10.04% to -83 cents per share on February 26
Q4'25
Est.
$-0.84
Q3'25
Beat
by $0.08
Q2'25
Missed
by $0.03
Q1'25
Missed
by $0.20
Q4'24
Beat
by $0.06
The last earnings report on November 05 showed earnings per share of -75 cents, beating the estimate of -83 cents. With 670.30K shares outstanding, the current market capitalization sits at 2.66B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. DYN showed earnings on November 05, 2025. You can read more about the earnings report here.